2024-10-26 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis:

**1. Performance & Relative Strength:**

Merck & Co Inc (MRK) has delivered a cumulative return of 64.51%, lagging behind the S&P 500 (VOO) with a cumulative return of 135.48%. This results in a current relative performance of -70.97, placing it at the 14.47th percentile of its historical performance range.  

**2. Recent Price Movement:**

* **Closing Price:** $105.88 (Last Market: $104.27)
* **5-Day Moving Average:** $106.69
* **20-Day Moving Average:** $109.77
* **60-Day Moving Average:** $113.59

The stock is currently trading below its 5, 20, and 60-day moving averages, indicating a potential downward trend. 

**3. Technical Indicators:**

* **RSI:** 33.75 - Indicates a potentially oversold condition.
* **PPO:** -0.26 - Suggests a bearish sentiment.
* **Delta_Previous_Relative_Divergence:** -11.7 (Short-term downtrend)
* **Expected_Return:** 0.0% - Over the next 2 years, the stock is expected to deliver a return equivalent to the S&P 500. 

**4. Recent Earnings & Outlook:**

| Date       | EPS       | Revenue          |
|------------|-----------|-------------------|
| 2024-08-05 | 2.15     | 16.11 B$        |
| 2024-05-03 | 1.88     | 15.78 B$        |
| 2023-11-03 | 1.87     | 15.96 B$        |
| 2023-08-07 | -2.35    | 15.04 B$        |
| 2024-08-05 | -2.35    | 15.04 B$        |

Merck's most recent earnings (2024-08-05) were $2.15 per share, exceeding analysts' expectations by a significant margin. However, the company's revenue growth remains somewhat stagnant. 

**5. News & Recent Issues:**

[Insert news regarding the company's recent earnings, recent market outlook, analyst opinions and performance highlights.]

**6. Summary:**

Merck & Co Inc (MRK) is a large pharmaceutical company with a strong history and a well-established position in the market. Despite a recent downtrend in the stock price, the company delivered strong earnings in its last quarter, exceeding analyst expectations. While the company faces challenges in maintaining consistent revenue growth, its strong financial performance and established position in the pharmaceutical industry suggest a long-term potential. 

**7. Report in English:**

## Merck & Co Inc (MRK) Stock Analysis:

**1. Performance & Relative Strength:**

Merck & Co Inc (MRK) has delivered a cumulative return of 64.51%, which lags behind the S&P 500 (VOO) with a cumulative return of 135.48%. This results in a current relative performance of -70.97, placing it at the 14.47th percentile of its historical performance range.  

**2. Recent Price Movement:**

* **Closing Price:** $105.88 (Last Market: $104.27)
* **5-Day Moving Average:** $106.69
* **20-Day Moving Average:** $109.77
* **60-Day Moving Average:** $113.59

The stock is currently trading below its 5, 20, and 60-day moving averages, indicating a potential downward trend. 

**3. Technical Indicators:**

* **RSI:** 33.75 - Indicates a potentially oversold condition.
* **PPO:** -0.26 - Suggests a bearish sentiment.
* **Delta_Previous_Relative_Divergence:** -11.7 (Short-term downtrend)
* **Expected_Return:** 0.0% - Over the next 2 years, the stock is expected to deliver a return equivalent to the S&P 500. 

**4. Recent Earnings & Outlook:**

| Date       | EPS       | Revenue          |
|------------|-----------|-------------------|
| 2024-08-05 | 2.15     | 16.11 B$        |
| 2024-05-03 | 1.88     | 15.78 B$        |
| 2023-11-03 | 1.87     | 15.96 B$        |
| 2023-08-07 | -2.35    | 15.04 B$        |
| 2024-08-05 | -2.35    | 15.04 B$        |

Merck's most recent earnings (2024-08-05) were $2.15 per share, exceeding analysts' expectations by a significant margin. However, the company's revenue growth remains somewhat stagnant. 

**5. News & Recent Issues:**

[Insert news regarding the company's recent earnings, recent market outlook, analyst opinions and performance highlights.]

**6. Summary:**

Merck & Co Inc (MRK) is a large pharmaceutical company with a strong history and a well-established position in the market. Despite a recent downtrend in the stock price, the company delivered strong earnings in its last quarter, exceeding analyst expectations. While the company faces challenges in maintaining consistent revenue growth, its strong financial performance and established position in the pharmaceutical industry suggest a long-term potential. 

**7. Company Overview:**

Merck & Co Inc is a global pharmaceutical company that develops, manufactures, and markets prescription medicines, vaccines, and animal health products. The company operates in over 140 countries and employs over 70,000 people.
